You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
Evolution of an Adaptable Prosthetic Foot Design for Normalization of Biomechanics During Community ParticipationSBC: OHIO WILLOW WOOD COMPANY, THE Topic: NICHD
Evolution of an Adaptable Prosthetic Foot Design for Normalization ofBiomechanics During Community Participation Summary/AbstractThe vision of this project is to improve the functional physical mobility of people with lower extremity amputations especially on uneven ground, side-slopes or when foot placement varies from side-to-side. People with amputations will be enabled to confidently participa ...STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: VIROGENOMICS BIODEVELOPMENT INC Topic: R41
Methamphetamine use disorder is associated with damage to regions of the brain that control cognitive and psychiatric functionOne third to one half of adults with methamphetamine use disorder experience cognitive impairments and other psychiatric symptoms that significantly impact treatment outcomesincreased relapse and lower treatment retention ratesMounting evidence demonstrates how immune facto ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: Z-Quick, LLC Topic: NIAID
Project Summary Abstract The advent of the Zika virusZIKVepidemic around the world has and will cause problems for the correct diagnosis of flavivirus infectionsFor many yearsDENV serological diagnosis was relatively straightforwardHoweverafter the recent ZIKV epidemiccross reactive antibodiesAbsgenerated after ZIKV infection will bind to DENV even if the patient has never had DENVThe only FDA app ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: ENGINEERING RESOURCES GROUP INC Topic: NIEHS
PROJECT SUMMARY Genomic instabilityinduced by DNA damageand partly mitigated by DNA repair and antioxidantsplays a critical role in the pathogenesis of many major human diseasessuch as neurodegenerationcancer and cardiovascular diseasetogether with agingThere is a critical need for automated assays that can perform these assessmentsand bring them into greater routine usewhich will help advance our ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: Op-T-Mune, Inc Topic: NIAID
Type 1 Diabetes (T1D) affects an ever growing population. While this disease typically has been associated with juveniles, the disease in adult populations is rapidly increasing. The defining clinical component is insulin loss, which occurs because of sustained inflammation in the islets. At present there is no means to prevent or reverse insulin loss. A major inflammatory pathway in T1D that cont ...STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: SWITCHBOX INC Topic: DHA18B001
Most standard-of-care tools and techniques for evaluating neck disorders are subjective, unreliable, and do not provide actionable information for providers, payers, and organizations to deliver efficient and effective care. This lack of objective neck heSTTR Phase I 2019 Department of DefenseDefense Health Agency
Development of Spleen Tyrosine Kinase (SYK) negative allosteric modifiers for therapeutic intervention in Alzheimer's disease.SBC: ARCHER PHARMACEUTICALS, INC. Topic: NIA
Pathological hallmarks of Alzheimerandapos s diseaseADinclude extracellular deposits of Apeptidesintraneuronal aggregates of abnormally phosphorylated tau protein and neuroinflammationMost proposed AD disease modifying therapies have focused on strategies that reduce brain Aamyloid or tau pathological accumulationHoweversuch approaches have been unsuccessful in late stage AD clinical trials and ma ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: ASPIREBIO CORP Topic: 101
PROJECT SUMMARY Opioid drugs are powerful analgesicsbut their side effect profile strongly limits their useIndeedtheir addictive properties have led to an epidemic of abuse in the US that accounts forof the global utilization of prescription opioid analgesics in the USwith a market of over $billion per yearPrevious studies have shown that the endocannabinoid neurotransmitteranandamidecontrols noci ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: BERTEC CORP Topic: NIA
Falls are a significant source of early morbidity and mortality in the aging populationyet the neurologicalsensoryand motor changes that lead to increased fall risk often escape early identification and interventionVital signs are commonly used in clinical settings to assess the cardiovascular systemblood pressureheart rateimmune systembody temperatureand the respiratory systemrespiratory rateto e ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: Myolex Inc Topic: NIAMS
PROJECT SUMMARYAcute compartment syndromeACSremains one of the most devastating and often overlooked traumatic musculoskeletal disorders in clinical practiceIn this conditionpressure increases in one of the body s spacelimited compartmentsdue most commonly to direct trauma or bone fractureresulting ultimately in an ischemic injury to all of the compartment s contentsincluding muscle and nerveOnce ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health